Fabhalta (iptacopan) - Novartis
prednisone - Generic mfg.
mycophenolate mofetil - Generic mfg.
C3-Dominant Glomerulonephritis Mimicking Malignant Nephrosclerosis in Hypertensive Emergency (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #SA-PO0692; Pres time: Oct 24, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Ten days earlier, he developed a generalized pruritic rash treated with a 7-day course of prednisone...Mycophenolate mofetil (MMF) was initiated after corticosteroids worsened blood pressure control, resulting in rash improvement. Although iptacopan was considered, insurance denial precluded initiation...Reduction in proteinuria remains the primary therapeutic goal and strongest predictor of renal outcomes. While newly approved complement inhibitors offer targeted therapy, long-term outcome data remain limited, and no therapy has demonstrated prevention of post-transplant recurrence." 
Acute Kidney Injury • Fibrosis • Glomerulonephritis • Hepatitis B • Hepatology • Human Immunodeficiency Virus • Immunology • Infectious Disease • Lupus Nephritis • Musculoskeletal Pain • Nephrology • Pulmonary Disease • Renal Disease • Vasculitis
https://www.asn-online.org/education/kidneyweek/2026/program-abstract.aspx?controlId=4555373
 
Boney Jayeshkumar Lapsiwala; Karthik Kasireddy; Marisha Rai Sharma; Rupali Prabhukhot; Victor Alejandro Canela-Samaniego
 
Oct 2, 2026
 
Prev Next